Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
Saved in:
| Title: | Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial. |
|---|---|
| Authors: | Franek E; Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland., Gerstein HC; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada., Riddle MC; Department of Medicine, Oregon Health & Science University, Portland, Oregon., Nicolay C; Eli Lilly and Company, Indianapolis, Indiana., Hickey A; Eli Lilly and Company, Indianapolis, Indiana., Botros FT; Eli Lilly and Company, Indianapolis, Indiana., Loo LS; Eli Lilly and Company, Indianapolis, Indiana. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Sep; Vol. 24 (9), pp. 1753-1761. Date of Electronic Publication: 2022 May 30. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
